SteelPeak Wealth LLC Acquires 1,005 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

SteelPeak Wealth LLC raised its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 40.6% during the fourth quarter, HoldingsChannel.com reports. The fund owned 3,480 shares of the biopharmaceutical company’s stock after purchasing an additional 1,005 shares during the period. SteelPeak Wealth LLC’s holdings in Alnylam Pharmaceuticals were worth $819,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Huntington National Bank boosted its stake in shares of Alnylam Pharmaceuticals by 91.8% during the third quarter. Huntington National Bank now owns 94 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 45 shares in the last quarter. Hollencrest Capital Management acquired a new position in Alnylam Pharmaceuticals in the 3rd quarter valued at approximately $29,000. Washington Trust Advisors Inc. bought a new position in shares of Alnylam Pharmaceuticals during the third quarter valued at $42,000. True Wealth Design LLC lifted its holdings in shares of Alnylam Pharmaceuticals by 15,300.0% during the third quarter. True Wealth Design LLC now owns 154 shares of the biopharmaceutical company’s stock worth $42,000 after purchasing an additional 153 shares during the period. Finally, Harvest Fund Management Co. Ltd bought a new stake in shares of Alnylam Pharmaceuticals in the third quarter worth $45,000. Institutional investors own 92.97% of the company’s stock.

Insider Activity at Alnylam Pharmaceuticals

In related news, CMO Pushkal Garg sold 52,592 shares of the business’s stock in a transaction dated Monday, January 27th. The shares were sold at an average price of $285.00, for a total value of $14,988,720.00. Following the transaction, the chief marketing officer now directly owns 11,989 shares of the company’s stock, valued at approximately $3,416,865. The trade was a 81.44 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Phillip A. Sharp sold 11,250 shares of Alnylam Pharmaceuticals stock in a transaction dated Thursday, January 23rd. The stock was sold at an average price of $275.00, for a total transaction of $3,093,750.00. The disclosure for this sale can be found here. Over the last three months, insiders sold 73,964 shares of company stock valued at $20,622,925. 1.50% of the stock is owned by insiders.

Alnylam Pharmaceuticals Stock Down 1.9 %

ALNY opened at $273.99 on Thursday. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $141.98 and a fifty-two week high of $304.39. The firm has a market capitalization of $35.34 billion, a P/E ratio of -104.58 and a beta of 0.34. The company’s 50-day moving average is $249.42 and its 200 day moving average is $260.65. The company has a debt-to-equity ratio of 31.64, a current ratio of 2.75 and a quick ratio of 2.69.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its earnings results on Thursday, October 31st. The biopharmaceutical company reported ($0.87) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.36). The business had revenue of $500.90 million for the quarter, compared to analysts’ expectations of $532.91 million. The firm’s quarterly revenue was down 33.3% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.15 earnings per share. Research analysts expect that Alnylam Pharmaceuticals, Inc. will post -2.24 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

ALNY has been the topic of a number of analyst reports. Bank of America upped their price target on Alnylam Pharmaceuticals from $307.00 to $314.00 and gave the company a “buy” rating in a research report on Monday, October 14th. Wolfe Research cut Alnylam Pharmaceuticals from a “peer perform” rating to an “underperform” rating in a research note on Tuesday, November 12th. Chardan Capital reissued a “buy” rating and issued a $300.00 price target on shares of Alnylam Pharmaceuticals in a research note on Friday, November 1st. William Blair reaffirmed an “outperform” rating on shares of Alnylam Pharmaceuticals in a research report on Tuesday, November 19th. Finally, StockNews.com lowered shares of Alnylam Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, January 9th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating and nineteen have issued a buy rating to the company’s stock. According to data from MarketBeat, Alnylam Pharmaceuticals presently has an average rating of “Moderate Buy” and an average price target of $298.61.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.